We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.62%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$720M
AUM Growth
-$59.6M
(-7.6%)
Cap. Flow
-$36.5M
Cap. Flow
% of AUM
-5.06%
Top 10 Holdings %
Top 10 Hldgs %
17.21%
Holding
510
New
74
Increased
122
Reduced
203
Closed
86
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$4.08M |
| 2 |
JBTM
JBT Marel
JBTM
|
+$3.91M |
| 3 |
PRSU
Pursuit Attractions and Hospitality Inc
PRSU
|
+$3.66M |
| 4 |
Northern Oil and Gas
NOG
|
+$3.45M |
| 5 |
Devon Energy
DVN
|
+$3.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DEN
Denbury Inc.
DEN
|
+$7.07M |
| 2 |
Reliance Steel & Aluminium
RS
|
+$5.93M |
| 3 |
CHX
ChampionX
CHX
|
+$4.74M |
| 4 |
Accenture
ACN
|
+$4.11M |
| 5 |
On Holding
ONON
|
+$3.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Consumer Discretionary | 17.64% |
| 3 | Industrials | 15.79% |
| 4 | Healthcare | 11.67% |
| 5 | Financials | 10.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BELFB
176
Bel Fuse Inc Class B
BELFB
$3.88B
| $1.16M | 0.16% |
24,386
+17,925
| +277% | +$924K |
|
177
Hackett Group
HCKT
$245M
| $1.16M | 0.16% |
49,206
+22,384
| +83% | +$521K |
|
178
Vanguard Mid-Cap ETF
VO
$106B
| $1.15M | 0.16% |
22,020
| – | – |
|
179
Zegna
ZGN
$3.84B
| $1.13M | 0.16% |
81,273
+23,227
| +40% | +$339K |
|
180
Blackstone
BX
$104B
| $1.12M | 0.16% |
10,498
-675
| -6% | -$70.3K |
|
181
FS KKR Capital
FSK
$2.98B
| $1.1M | 0.15% |
55,874
-2,625
| -4% | -$52.5K |
|
|
BRSL
182
Brightstar Lottery PLC
BRSL
$1.91B
| $1.1M | 0.15% |
36,123
-4,849
| -12% | -$155K |
|
183
Veeco
VECO
$3.15B
| $1.08M | 0.15% |
38,427
+22,087
| +135% | +$609K |
|
184
Ero Copper
ERO
$2.71B
| $1.08M | 0.15% |
+62,445
| New | +$1.28M |
|
185
Alphatec Holdings
ATEC
$1.27B
| $1.07M | 0.15% |
82,873
-81,003
| -49% | -$1.27M |
|
186
Main Street Capital
MAIN
$4.97B
| $1.07M | 0.15% |
26,369
-1,481
| -5% | -$60.4K |
|
187
Curtiss-Wright
CW
$27.7B
| $1.07M | 0.15% |
5,447
+855
| +19% | +$169K |
|
188
Jabil
JBL
$32.8B
| $1.05M | 0.15% |
8,272
+1,067
| +15% | +$117K |
|
189
Chesapeake Utilities
CPK
$3.26B
| $1.04M | 0.14% |
10,672
+4,849
| +83% | +$549K |
|
190
Krystal Biotech
KRYS
$9.88B
| $1.04M | 0.14% |
8,989
-2,664
| -23% | -$325K |
|
191
Meta Platforms (Facebook)
META
$1.51T
| $1.02M | 0.14% |
3,400
-660
| -16% | -$199K |
|
192
Lattice Semiconductor
LSCC
$17.6B
| $1.02M | 0.14% |
11,862
+73
| +0.6% | +$6.59K |
|
193
Arcos Dorados Holdings
ARCO
$1.73B
| $1.01M | 0.14% |
106,493
-54,157
| -34% | -$559K |
|
194
Encompass Health
EHC
$11.2B
| $1M | 0.14% |
14,944
-577
| -4% | -$39.7K |
|
195
Newmark Group
NMRK
$2.73B
| $991K | 0.14% |
+154,080
| New | +$1.07M |
|
196
Eli Lilly
LLY
$1.07T
| $951K | 0.13% |
1,771
-230
| -11% | -$119K |
|
197
Perion Network
PERI
$367M
| $951K | 0.13% |
31,055
-26,478
| -46% | -$888K |
|
198
ExxonMobil
XOM
$651B
| $946K | 0.13% |
8,047
+384
| +5% | +$42.1K |
|
199
Aaon
AAON
$8.41B
| $941K | 0.13% |
16,552
-12,580
| -43% | -$799K |
|
200
Owens Corning
OC
$11.5B
| $941K | 0.13% |
6,895
-2,546
| -27% | -$350K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q3 2023 Portfolio in Review
As of Q3 2023, Advisory Research held 510 positions worth $720M, down 7.6% from $780M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Advisory Research withdrew a net $36.5M in Q3 2023, closing 86 positions and reducing 203 holdings. Its most notable exit was Livent Corporation, an estimated $2.81M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Advisory Research opened a new position in JBT Marel worth $3.67M.
- Advisory Research's largest Q3 2023 buy was JBT Marel: 34,900 shares worth $3.67M.
- Advisory Research added most to GSK in Q3 2023, an estimated $4.08M increase.
- Advisory Research's biggest Q3 2023 reduction was Denbury Inc., cutting an estimated $7.07M.
- Advisory Research fully exited Livent Corporation in Q3 2023, selling an estimated $2.81M.
- Advisory Research's ten largest holdings make up 17% of its $720M portfolio in Q3 2023.
- Advisory Research opened 74 new positions and closed 86 in Q3 2023.
- Advisory Research's portfolio value fell 7.6% quarter-over-quarter to $720M.
Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.